Patient Outcomes Impacted by HoFH
Dr Brinton provides insights regarding prognosis for patients with HoFH.
Overview of Homozygous and Heterozygous Familial Hypercholesterolemia (HoFH)
Eliot Brinton, MD, opens a discussion surrounding the treatment landscape for patients with homozygous familial hypercholesterolemia (HoFH).
Role of Gene Therapy for Rett Syndrome Treatment
David Lieberman, MD, PhD, reviews the potential role and the goals of gene therapy in the treatment of Rett syndrome.
Future Treatment Landscape for Patients With LN
In their closing thoughts, experts emphasize their optimism regarding the direction of LN treatment strategies and resources.
Unmet Needs Surrounding Treatment of Lupus Nephritis
Drs Wells and Larranaga discuss unmet needs in the treatment landscape for patients with lupus nephritis.
Barriers to Care for Patients With LN
Drs Larranaga and Wells describe challenges impacting access to care for patients with LN.
What Would You Change About the EOM?
Constructive advice on improving the Enhancing Oncology Model (EOM) from our expert panel.
Does Pooling Make Sense?
The Enhancing Oncology Model allows pooling of groups of practices for quality measurement, which was not permitted under the OCM.
ASCERTAIN Trial Overview
Guillermo Garcia-Manero, MD, highlights the ASCERTAIN trial in his opening thoughts surrounding MDS in this ASH 2022 post-conference perspective.
Phase III Apply-PNH Study Overview
Carlos M. De Castro, MD, highlights the phase III Apply-PNH study presented at ASH 2022.
Educating Patients to Self-Monitor Disease Progression of COPD
Patient education is critical for self-monitoring of COPD disease progression.
Determining Appropriate Changes to COPD Treatment Strategy
An expert panel discusses appropriate transitions and adjustments to COPD treatment approaches.
Early Intervention in the Management of Diabetes
Medical experts share considerations for early intervention in patients with diagnoses of diabetes.
Risk Factors Associated with Diabetes
Medical experts navigate risk factors associated with diabetes.
MAIA Study and Subgroup Analysis
Ryan Haumschild, PharmD, MS, MBA, leads a panel in a conversation reviewing the MAIA study.
Front-line Treatment Management for Patients with Multiple Myeloma (MM)
Key opinion leaders open a discussion surrounding the current treatment landscape of multiple myeloma (MM).
Small Practices and Dual Risk: Considerations and Approaches
Asking for help to prepare for the Enhancing Oncology Model (EOM) and 2-sided risk is advised, say panelists experienced with the Oncology Care Model (OCM).
Changes to MEOS and Barriers to Entry
As terms for Monthly Enhanced Oncology Services (MEOS) payments are set to change under the EOM, panelists worry that the barriers to entry to value-based care will be too high for practices that did not participate in the OCM.
Patient-Support Services and Programs for Patients With Gastroesophageal Cancer
In her final thoughts regarding gastroesophageal cancer, Laura Bobolts, PharmD, BCOP, overviews patient support services and programs.
Cost-Effective Analyses for Upper GI and Esophageal Cancer Treatment
Laura Bobolts, PharmD, BCOP, shares her perspective surrounding cost-effective analyses surrounding GI and esophageal cancers.
Evaluating Gastroesophageal Cancer Pathway Decisions
Laura Bobolts, PharmD, BCOP, discusses GI and esophageal cancer treatment pathway decisions.
Factors Affecting MDD Treatment Adherence
Expert panelists consider factors affecting treatment adherence for patients with MDD.
Population Health Approach in MDD
Drs Weaver and Chitre illustrate a population health approach strategy for MDD.
AURORA 2 Study of Voclosporin in LN Treatment
Jorge Larranaga, MD, discusses the AURORA 2 study and its emphasis on voclosporin.
Utilizing Belimumab and Voclosporin in LN Treatment Pathway
Belimumab and voclosporin are highlighted as key contributors to the lupus nephritis treatment landscape.
Diabetes in the Presence of Cardiovascular Disease
Jaime Murillo, MD, discusses the impact of diabetes on cardiovascular disease.
Comorbidities Associated with Diabetes
Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE, leads a discussion surrouding early intervention in the management of type 2 diabetes.
Is Five Years Long Enough?
Panelists see the 5-year period of the Enhancing Oncology Model as reasonable; they would like see some progress toward permanent value-based payment structures.
Addressing Health Equity and Social Needs
Addressing cancer patients' lack of housing or food insecurity affects care outcomes, but how can the Center for Medicare and Medicaid Innovation build this into a reward structure?
COPD Triple Therapy: Appropriate Patient Population
Key opinion leaders highlight the triple therapy approach from the most recent GOLD guidelines, including ICS, long-acting beta-agonist (LABA), and long-acting muscarinic antagonist (LAMA).